Raffles Medical Group (BSL) AI Stock Analysis

• Market Cap: $1.88B
• Dividend Yield: 2.53%
• Average Volume (3M): 1.13M
• Price to Earnings (P/E): 29.2
• Beta (1Y): 0.57
• Revenue Growth: 8.90%
• EPS Growth: 4.57%
• Country: SG
• Employees: 2,989
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.02
• Shares Outstanding: 1,884,544,900
• 10 Day Avg. Volume: 1,100,720
• 30 Day Avg. Volume: 1,133,593
• PEG Ratio: -0.82
• Price to Book (P/B): 1.50
• Price to Sales (P/S): 2.10
• P/FCF Ratio: 24.16
• Enterprise Value/Market Cap: 0.86
• Enterprise Value/Revenue: 2.11
• Enterprise Value/Gross Profit: 4.63
• Enterprise Value/Ebitda: 13.73
• 1Y Price Target: $1.32
• Price Target Upside: 33.69% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 67 Neutral
• Price Target: S$1.00 ▲(1.01% Upside)

Raffles Medical Group's overall stock score is driven by its strong financial performance, characterized by robust revenue growth and low leverage. However, the valuation is relatively high, and technical indicators suggest a neutral market sentiment. The absence of earnings call data and corporate events limits further insights.

Positive Factors

Revenue Growth

Consistent revenue growth indicates a robust market position and effective service expansion, supporting long-term financial stability.

Leadership Enhancement

New leadership appointments are likely to enhance operational efficiency and strategic direction, fostering growth and market expansion.

Low Leverage

Low leverage enhances financial flexibility, allowing the company to invest in growth opportunities without significant debt burden.

Negative Factors

Margin Contraction

Declining margins may pressure profitability and limit reinvestment capacity, potentially impacting long-term competitive positioning.

Free Cash Flow Decline

A decline in free cash flow relative to net income may indicate increased capital needs, affecting liquidity and financial flexibility.

Profitability Margins

Contracting profitability margins could challenge the company's ability to sustain earnings growth and shareholder returns over time.

Raffles Medical Group Business Overview & Revenue Model

Company Description

Raffles Medical Group (BSL) is a leading integrated healthcare provider based in Singapore, offering a comprehensive range of medical services across various sectors, including primary care, specialty care, and diagnostic services. The company operates a network of clinics and hospitals, providing outpatient and inpatient care, health screening services, and corporate healthcare solutions. Raffles Medical Group is known for its commitment to quality healthcare, employing advanced medical technologies and a team of experienced healthcare professionals.

How the Company Makes Money

Raffles Medical Group generates revenue through multiple streams, primarily from its outpatient and inpatient services, including consultations, treatments, and surgeries. The company operates its own hospitals and a network of clinics, which contribute significantly to its earnings. Additionally, Raffles Medical Group offers health screening packages and corporate health services, catering to businesses seeking to improve employee health and productivity. The company also engages in partnerships with insurers and corporate clients, providing tailored healthcare solutions that enhance its revenue base. Furthermore, Raffles Medical Group's focus on expanding its services and facilities, as well as its investment in technology and patient care, supports its financial growth.

Raffles Medical Group Financial Statement Overview

Summary

Raffles Medical Group presents a stable financial position with strong revenue growth and low leverage. While profitability margins have contracted, the company maintains operational efficiency. The cash flow position is solid, supporting ongoing operations and potential growth initiatives.

Income Statement

Raffles Medical Group shows a strong revenue growth trajectory with a TTM growth rate of 8.41%. However, margins have declined from previous years, with the TTM gross profit margin at 45.56% compared to 64.68% in 2024. The net profit margin remains stable at around 8.3%. The company demonstrates consistent EBIT and EBITDA margins, indicating operational efficiency despite the margin contraction.

Balance Sheet

The balance sheet is robust with a low debt-to-equity ratio of 0.082, indicating low leverage and financial stability. The return on equity is moderate at 6.16%, reflecting a stable return on shareholders' investments. The equity ratio is strong, suggesting a solid capital structure with a significant portion of assets financed by equity.

Cash Flow

The cash flow statement shows a positive trend with a free cash flow growth rate of 18.73% in the TTM period. The operating cash flow to net income ratio is healthy, indicating good cash generation relative to net income. However, the free cash flow to net income ratio has slightly decreased, suggesting potential reinvestment or increased capital expenditures.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	765.17M	751.56M	708.03M	822.92M	723.79M	568.20M
Gross Profit	348.63M	486.14M	315.94M	639.98M	580.52M	432.43M
EBITDA	117.45M	133.40M	132.89M	235.87M	161.27M	125.09M
Net Income	63.71M	62.24M	90.15M	143.21M	84.17M	65.89M
Balance Sheet
Total Assets	1.49B	1.53B	1.53B	1.50B	1.55B	1.40B
Cash, Cash Equivalents and Short-Term Investments	334.18M	343.67M	343.60M	253.13M	264.99M	203.11M
Total Debt	83.83M	88.17M	124.70M	96.14M	198.13M	232.79M
Total Liabilities	455.26M	465.81M	484.38M	467.30M	568.67M	489.74M
Stockholders Equity	1.02B	1.05B	1.03B	1.02B	960.79M	899.00M
Cash Flow
Free Cash Flow	97.85M	65.34M	168.79M	170.93M	107.24M	69.67M
Operating Cash Flow	108.29M	86.25M	189.31M	196.22M	160.11M	133.15M
Investing Cash Flow	-3.40M	-9.87M	-12.41M	-22.83M	-52.20M	-62.19M
Financing Cash Flow	-85.58M	-76.20M	-85.52M	-183.70M	-46.87M	-20.88M

Raffles Medical Group Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.99
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:BSL, the sentiment is Negative. The current price of 0.99 is below the 20-day moving average (MA) of 1.00, below the 50-day MA of 1.00, and above the 200-day MA of 0.97, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.83 is Neutral, neither overbought nor oversold. The STOCH value of 22.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SG:BSL.

Raffles Medical Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BSL	―	$1.88B	29.15	6.20%	2.53%	8.90%	4.57%
1B1	―	S$52.29M	6.19	47.36%	5.82%	1.58%	115.29%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
A50	―	S$1.56B	―	-9.99%	―	12.39%	-400.00%

Raffles Medical Group Corporate Events

Raffles Medical Group Enhances Leadership with Key Appointments

Raffles Medical Group has strengthened its leadership team by appointing Dr. Kenneth Wu and Dr. Sarah Lu as Co-Managing Directors for its Singapore Healthcare division, alongside the introduction of Mr. Terence Foo as the new Chief Technology Officer. These strategic appointments are expected to enhance the operational and commercial management of the Group’s healthcare services in Singapore and Indochina, potentially improving service delivery and expanding its market presence.